SCHEMBL3511355

SCHEMBL3511355

CC(C)(C)N(C(=O)O)c1cccc(Oc2ccc([N+](=O)[O-])cn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 2/20 0.46
MAPT P10636 8/20 0.46
NPSR1 Q6W5P4 2/20 0.46
RAB9A P51151 1/20 0.45
PPARG P37231 1/20 0.44
LMNA P02545 5/20 0.42
HTT P42858 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
GAA P10253 2/20 0.42
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 5/20 0.41
RGS12 O14924 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511358 1.00 HSPB1 (0.46) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3134665 0.87 HSPB1 (0.56) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3134680 0.87 HSPB1 (0.56) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3512431 0.82 KDM4E (0.54) MAPTNPSR1RAB9AHTTL3MBTL1
SCHEMBL1260304 0.81 HSPB1 (0.60) HSPB1MAPTNPSR1RAB9ALMNA
SCHEMBL3510832 0.81 HSPB1 (0.52) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL3510827 0.81 HSPB1 (0.52) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL1260299 0.81 HSPB1 (0.60) HSPB1MAPTNPSR1RAB9ALMNA
SCHEMBL2450640 0.81 HSPB1 (0.53) HSPB1MAPTNPSR1RAB9APPARG
SCHEMBL2450636 0.81 HSPB1 (0.53) HSPB1MAPTNPSR1RAB9APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 HSPB1 3348/4885MAPT 4439/4885NPSR1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.